• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Susan Dallabrida named to PharmaVOICE 100

Susan Dallabrida named to PharmaVOICE 100

August 15, 2014
CenterWatch Staff

PHT has announced Susan Dallabrida, Ph.D., vice president of clinical science and consulting, is among this year’s PharmaVOICE 100 most inspiring professionals in the life sciences industries. Dallabrida is the 6th PHT executive to earn a place on the list. PHT is a provider of technologies used to collect patient-driven eData for clinical research.

Established 10 years ago by PharmaVOICE magazine, the PharmaVOICE 100 is an annual list of individuals recognized for their positive contributions to the industry. Dallabrida was chosen for her scientific expertise in offering the pharma, biotech and life sciences industries a combination of vision and practicality in using eClinical technologies that drive efficiencies within pragmatic research.

Philip Lee, PHT president and CEO, who was a 2011 PharmaVOICE 100 honoree, said, “Dallabrida has a well-earned reputation for leadership in developing technologies to provide evidence, data analysis and creative solutions that result in huge improvements in study design that is focused on the patient.”

Dallabrida has over 21 years of experience as a senior scientist, consultant and leader in clinical research and development, trial design and strategy and product development. She has significant regulatory experience for biologics and small molecules. Dallabrida has led cross-functional drug discovery and product development teams and collaborations in therapeutic areas including oncology, cardiovascular disease, hemophilia, dermatology, obesity and vascular disorders. She has a broad background in scientific presentations and writing with 21 publications, 14 grants, 3 patents, 18 awards, 43 conference presentations and 29 abstracts.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • InputinLights-360x240.png

    Seeking Patient Input Early Helps Ensure Minority Participation in Trials

  • Oncology-360x240.png

    Global Oncology Trial Launches Drop Dramatically During Pandemic, Study Shows

  • Qualification-360x240.png

    Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

  • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing